leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...147148149150151152153154155156157...235236»
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    Journal:  Leucovorin ameliorated methotrexate induced intestinal toxicity via modulation of the gut microbiota. (Pubmed Central) -  Aug 18, 2020   
    In conclusion, our results suggest that the balance and the composition of gut microbiota have an important role in the LV-mediated protection against MTX-induced intestinal toxicity. This work provides foundation of data in support of a new potential mechanism for the prevention of MTX-induced intestinal toxicity.
  • ||||||||||  Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  GEMFOX: FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX (clinicaltrials.gov) -  Aug 18, 2020   
    P3,  N=400, Recruiting, 
    This case demonstrates the importance of considering potential drug-drug interactions and the need for robust monitoring for OPAT in select groups. Not yet recruiting --> Recruiting | Trial completion date: Jan 2025 --> Jul 2025 | Initiation date: Jan 2020 --> Jul 2020 | Trial primary completion date: Jan 2025 --> Jul 2025
  • ||||||||||  Enrollment closed, Enrollment change, Trial primary completion date:  Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) -  Aug 17, 2020   
    P2,  N=24, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Jan 2025 --> Jul 2025 | Initiation date: Jan 2020 --> Jul 2020 | Trial primary completion date: Jan 2025 --> Jul 2025 Recruiting --> Active, not recruiting | N=50 --> 24 | Trial primary completion date: Jan 2017 --> Jun 2022
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly
    Enrollment closed, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases:  TAIPD1-HCC: HAIC Combined With PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC (clinicaltrials.gov) -  Aug 17, 2020   
    P2,  N=40, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=50 --> 24 | Trial primary completion date: Jan 2017 --> Jun 2022 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2021 --> Jul 2020
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    Journal:  Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma. (Pubmed Central) -  Aug 15, 2020   
    Methotrexate (MTX) in tumor cells is polyglutamylated and strongly binds to dihydrofolate reductase (DHFR) without competitive inhibition by leucovorin...Combination treatments were created using 4 HDACIs: panobinostat, vorinostat, sodium butyrate, and valproic acid...The combination of MTX and vorinostat decreased cell viability in vitro (P < .05) and tumor volumes in a subcutaneous model (P < .0001), and prolonged survival in an intracranial model (P < .01), relative to controls. HDACIs enhanced the therapeutic effect of MTX through increased polyglutamylation of MTX and concomitant downregulation of DHFR expression.
  • ||||||||||  dalutrafusp alfa (AGEN1423) / Agenus
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Aug 13, 2020   
    P1a/1b,  N=213, Recruiting, 
    Trial primary completion date: Aug 2020 --> Jul 2021 Trial completion date: Dec 2024 --> Aug 2026 | Trial primary completion date: Nov 2021 --> Aug 2025
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
    NCCN guideline, Journal:  NCCN Guidelines Updates: Pancreatic Cancer. (Pubmed Central) -  Aug 13, 2020   
    The NCCN Guidelines for Pancreatic Adenocarcinoma reflect these advances, and recommend that clinicians consider germline testing for all patients with pancreatic cancer and consider a molecular analysis for those with metastatic disease. The guidelines further recommend that clinicians consider adjuvant therapy with modified FOLFIRINOX (leucovorin/5-FU/irinotecan/oxaliplatin) for patients who are able to tolerate it.
  • ||||||||||  GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis
    Trial completion date, Trial primary completion date, Tumor cell:  Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas (clinicaltrials.gov) -  Aug 13, 2020   
    P=N/A,  N=19, Active, not recruiting, 
    The guidelines further recommend that clinicians consider adjuvant therapy with modified FOLFIRINOX (leucovorin/5-FU/irinotecan/oxaliplatin) for patients who are able to tolerate it. Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021
  • ||||||||||  sirexatamab (DKN-01) / Leap Therap
    Enrollment open, Combination therapy, Metastases:  DisTinGuish: A Study of DKN-01 in Combination With Tislelizumab  (clinicaltrials.gov) -  Aug 12, 2020   
    P2a,  N=72, Recruiting, 
    Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021 Not yet recruiting --> Recruiting
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
    Review, Journal, BRCA Biomarker, PARP Biomarker, IO Biomarker:  Pancreatic cancer. (Pubmed Central) -  Aug 11, 2020   
    Data on the benefit of PARP inhibition as maintenance therapy in patients with germline BRCA1 or BRACA2 mutations might prove to be a harbinger of advancement in targeted therapy. Additional research efforts are focusing on modulating the pancreatic tumour microenvironment to enhance the efficacy of the immunotherapeutic strategies.
  • ||||||||||  vancomycin / Generic mfg., leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    Journal:  Low-dose Methotrexate Toxicity in the Setting of Vancomycin-induced Acute Kidney Injury. (Pubmed Central) -  Aug 11, 2020   
    The condition was managed with leucovorin rescue therapy and sodium bicarbonate to enhance methotrexate excretion. Renally dosing methotrexate in patients on other nephrotoxic drugs, and monitoring creatinine clearance are methods for preventing such a toxicity.
  • ||||||||||  Trial completion date, Trial primary completion date:  QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed (clinicaltrials.gov) -  Aug 11, 2020   
    P1/2,  N=65, Active, not recruiting, 
    Renally dosing methotrexate in patients on other nephrotoxic drugs, and monitoring creatinine clearance are methods for preventing such a toxicity. Trial completion date: Dec 2019 --> Apr 2021 | Trial primary completion date: Dec 2019 --> Jan 2021
  • ||||||||||  Biomarker, Trial initiation date:  Neoadjuvant Therapy for Localized Rectal Adenocarcinoma (clinicaltrials.gov) -  Aug 10, 2020   
    P2,  N=45, Not yet recruiting, 
    Trial primary completion date: Oct 2024 --> Aug 2025 Initiation date: Jun 2020 --> Sep 2020
  • ||||||||||  Odomzo (sonidegib) / Sun Pharma
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer (clinicaltrials.gov) -  Aug 9, 2020   
    P1b,  N=39, Completed, 
    Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Sep 2021 --> Sep 2022 Active, not recruiting --> Completed | Trial completion date: Mar 2019 --> Nov 2019 | Trial primary completion date: Mar 2019 --> Nov 2019
  • ||||||||||  Trial completion date, Trial primary completion date, Metastases:  Short-course Radiotherapy (5 (clinicaltrials.gov) -  Aug 8, 2020   
    P1,  N=9, Recruiting, 
    Trial completion date: Jun 2021 --> Aug 2022 | Trial primary completion date: Jun 2020 --> Aug 2021 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
  • ||||||||||  Opdivo (nivolumab) / BMS
    Trial primary completion date:  CA209-8TT: Pan Tumor Rollover Study (clinicaltrials.gov) -  Aug 7, 2020   
    P2,  N=1200, Recruiting, 
    Phase classification: P3 --> P2 | N=548 --> 155 Trial primary completion date: Dec 2022 --> Aug 2025
  • ||||||||||  leucovorin calcium / Generic mfg.
    Review, Journal:  Cerebral folate deficiency: Analytical tests and differential diagnosis. (Pubmed Central) -  Aug 2, 2020   
    Other secondary causes of cerebral folate deficiency include the effects of drugs, immune response activation, toxic insults and oxidative stress. This review describes the absorption, transport and metabolism of folate within the body; analytical methods to measure folate species in blood, plasma and CSF; inherited and acquired causes of cerebral folate deficiency; and possible treatment options in those patients found to have cerebral folate deficiency.
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., Avastin (bevacizumab) / Roche
    Clinical, Journal:  Appendiceal Goblet Cell Carcinoid Successfully Treated with Bevacizumab plus mFOLFOX6 Regimen-A Case Report (Pubmed Central) -  Jul 30, 2020   
    Intraoperative findings included multiple disseminated nodules on the mesenterium surrounding the cecal tumor.The histopathologic diagnosis was poorly differentiated adenocarcinoma, which consisted of glandular proliferation of atypical epithelial cells and dispersed infiltration of goblet cells. Immunohistochemistry showed positively stained neuroendocrine markers, such as CD56, chromogranin, and synaptophysin.The patient was diagnosed with goblet cell carcinoid of the appendix and treated with combination chemotherapy of bevacizumab, fluorouracil, folinic acid, and oxaliplatin.He remained free from progression for over 1 and half years with this treatment.Subsequent chemotherapy was ineffective, and he passed away.There is no established chemotherapy regimen for goblet cell carcinoid, which has the aspects of both adenocarcinoma and neuroendocrine tumors.However, the present case suggested the efficacy of the mFOLFOX6 regimen in combination with bevacizumab for appendiceal goblet cell carcinoid.